Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND studyDavid T Yeung, Timothy P. Hughes, Nicholas Viiala et al.|Blood|2024Cited by 24
Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is RareDavid T Yeung, Timothy P. Hughes, Naranie Shanmuganathan et al.|Blood|2024Cited by 6
Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML StudyDavid T Yeung, On Behalf of the ALLG, Naranie Shanmuganathan et al.|Blood|2023Cited by 5
Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CMLDavid T Yeung, Timothy P. Hughes, Carolyn Grove et al.|Blood|2022Cited by 4